The fast-growing Israeli flavors and natural specialty fine ingredients company has made 37 acquisitions since 2013.
Cogentix, sold to Canadian company Laborie for $242 million, is the biggest success so far for Accelmed's investment model.
The Petah Tikva based cybersecurity company says Vaultive's cloud security product will enhance its privileged account security solution.
Israel's Ministry of Finance has reached agreement with Elbit Systems over the privatization of Israel Military Industry (IMI) Systems.
Unless acquiring Eurocom gives him control of Bezeq, Naty Saidoff is likely to withdraw, leaving the creditor banks without a debt arrangement.
The US company will buy the first 10% of Vonetize for $1.41 per share, a 490% premium on the share price, reflecting a company valuation of $50 million.
Businessman Moshe Sabah who is leading a consortium: Money for Negev Ceramics acquisition will come from a Jordanian investor.
Veridis deals in the environment, desalination, power production, and energy solutions.
Merck CEO Dr. Stefan Oschmann is reluctant to comment on Teva, but comparisons are inevitable.
The IDB controlling shareholder believes that Cellcom's share price is as high as it can get.
Argus's CEO and CMO talk about their competitive advantage and how they might expand from car cybersecurity.
Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.
More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.
Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.